Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Alendronate in Postmenopausal Osteoporotic Women with Prediabetes
ChiCTR2300070789Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis and prediabetes (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: HbA1c at 12 months. Planned start May 2023; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisprediabetes
Beyond the preview
Go deeper on ChiCTR2300070789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070789.